El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 

Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain

dc.contributor.authorCampa, Adela G. de la
dc.contributor.authorArdanuy Tisaire, María Carmen
dc.contributor.authorBalsalobre, Luz
dc.contributor.authorPérez Trallero, Emilio
dc.contributor.authorMarimón, José María
dc.contributor.authorFenoll, Asunción
dc.contributor.authorLiñares Louzao, Josefina
dc.date.accessioned2016-05-10T12:15:06Z
dc.date.available2016-05-10T12:15:06Z
dc.date.issued2009-06
dc.date.updated2016-05-10T12:15:11Z
dc.description.abstractAmong 4,215 Streptococcus pneumoniae isolates obtained in Spain during 2006, 98 (2.3%) were ciprofloxacin resistant (3.6% from adults and 0.14% from children). In comparison with findings from a 2002 study, global resistance remained stable. Low-level resistance (30 isolates with MIC 4-8 μg/mL) was caused by a reserpine-sensitive efflux phenotype (n = 4) or single topoisomerase IV (parC [n = 24] or parE [n = 1]) changes. One isolate did not show reserpine-sensitive efflux or mutations. High-level resistance (68 isolates with MIC ≥16 μg/mL) was caused by changes in gyrase (gyrA) and parC or parE. New changes in parC (S80P) and gyrA (S81V, E85G) were shown to be involved in resistance by genetic transformation. Although 49 genotypes were observed, clones Spain9V-ST156 and Sweden15A-ST63 accounted for 34.7% of drug-resistant isolates. In comparison with findings from the 2002 study, clones Spain14-ST17, Spain23F-ST81, and ST8819F decreased and 4 new genotypes (ST9710A, ST57016, ST43322, and ST71733) appeared in 2006.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec615326
dc.identifier.issn1080-6040
dc.identifier.pmid19523289
dc.identifier.urihttps://hdl.handle.net/2445/98471
dc.language.isoeng
dc.publisherCenters for Disease Control and Prevention
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.3201/eid1506.080684
dc.relation.ispartofEmerging Infectious Diseases, 2009, vol. 15, num. 6, p. 905-911
dc.relation.urihttp://dx.doi.org/10.3201/eid1506.080684
dc.rightsDomini públic / Public domain
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationEstreptococs
dc.subject.classificationPneumococs
dc.subject.classificationInfeccions per pneumococs
dc.subject.classificationVacuna antipneumocòccica
dc.subject.classificationResistència als medicaments
dc.subject.classificationEspanya
dc.subject.otherStreptococcus
dc.subject.otherStreptococcus pneumonia
dc.subject.otherPneumococcal Infections
dc.subject.otherPneumococcal vaccine
dc.subject.otherDrug resistance
dc.subject.otherSpain
dc.titleChanges in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
615326.pdf
Mida:
469.32 KB
Format:
Adobe Portable Document Format